Lagan E., Gannon D., Silva A.J., Bibawi P., Doherty A.M., Nimmo D., McCole R., Monger C., Genesi G.L., Vanderlinden A., Innes J.A., Jones C.L.E., Yang L., Chen B., van Mierlo G., Jansen P.W.T.C., Pednekar C., Von Kriegsheim A., Wynne K., Sanchez-Rivera F.J., Soto-Feliciano Y.M., Carcaboso A.M., Vermeulen M., Oliviero G., Chen C.-W., Phillips R.E., Bracken A.P., Brien G.L., A specific form of cPRC1 containing CBX4 is co-opted to mediate oncogenic gene repression in diffuse midline glioma, Molecular Cell, 85, (11), 2025, p2110 - 2127.e7, p2110-2127.e7 ,
Journal Article,
PUBLISHED
DOI
|
McCole R, Nolan J, Reck DM, Monger C, Rustichelli S, Conway E, Brien GL, Wang C, Deevy O, Neikes HK, Bashore FM, Mooney A, Flavin R, Vandenberghe E, Flanigan SF, Pasini D, Davidovich C, Vermeulen M, James LI, Healy E, Bracken AP., A conserved switch to less catalytically active Polycomb repressive complexes in non-dividing cells., Cell reports, 44, (1), 2025, p115192 ,
Journal Article,
PUBLISHED
DOI
|
Glancy E, Wang C, Tuck E, Healy E, Amato S, Neikes HK, Mariani A, Mucha M, Vermeulen M, Pasini D, Bracken AP, PRC2.1- and PRC2.2-specific accessory proteins drive recruitment of different forms of canonical PRC1, MOLECULAR CELL, 2023,
Journal Article,
PUBLISHED
|
Brien GL, Bressan RB, Monger C, Gannon D, Lagan E, Doherty AM, Healy E, Neikes H, Fitzpatrick DJ, Deevy O, Grant V, Marqués-Torrejón MA, Alfazema N, Pollard SM, Bracken AP., Simultaneous disruption of PRC2 and enhancer function underlies histone H3.3-K27M oncogenic activity in human hindbrain neural stem cells., Nature Genetics, 53, (8), 2021, p1221 - 1232,
Journal Article,
PUBLISHED
TARA - Full Text
|
Glancy, E. and Ciferri, C. and Bracken, A.P., Structural basis for PRC2 engagement with chromatin, Current Opinion in Structural Biology, 67, 2020, p135-144 ,
Journal Article,
PUBLISHED
TARA - Full Text
DOI
|
Lanigan F, Gallagher WM and Bracken AP., 'A method of predicting risk of recurrence of cancer', TCD and UCD, US 10,557,175, 2020, Jointly owned by TCD and UCD,
Notes: [The invention relates to a method of predicting the risk of tumour recurrence in a subject. Specifically, the invention relates to a method of predicting the risk of early-stage node -negative breast cancer, prostate cancer and other tumour recurrence],
Patent,
GRANTED
URL
|
Healy E, Mucha M, Glancy E, Fitzpatrick DJ, Conway E, Neikes HK, Monger C, Van Mierlo G, Baltissen MP, Koseki Y, Vermeulen M, Koseki H, and Bracken AP. , PRC2.1 and PRC2.2 synergize to co-ordinate H3K27 tri-methylation, Molecular Cell, 2019, p437-452.e6 ,
Journal Article,
PUBLISHED
DOI
|
Deevy O and Bracken AP., PRC2 functions in development and congenital disorders, Development, 146, (19), 2019, pdev181354 ,
Journal Article,
PUBLISHED
TARA - Full Text
DOI
|
Bracken AP, Brien GL and Verrijzer CP., Dangerous Liaisons: Interplay between SWI/SNF, NuRD and Polycomb in Chromatin Regulation and Cancer. , Genes & Development, 33, 2019, p1 - 24,
Journal Article,
PUBLISHED
TARA - Full Text
DOI
|
Lanigan F, Gallagher WM and Bracken AP., 'A method of predicting risk of recurrence of cancer,', TCD and UCD, EP3194621, 2019, Jointly owned by TCD and UCD,
Notes: [The invention relates to a method of predicting the risk of tumour recurrence in a subject. Specifically, the invention relates to a method of predicting the risk of early-stage node -negative breast cancer, prostate cancer and other tumour recurrence],
Patent,
GRANTED
URL
|
|